Skip to main content

Table 3 Adverse events reported by more than one patient in any treatment period (treated set)

From: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

  Patients, n (%)
  Tiotropium Respimat ® 5 μg Tiotropium Respimat ® 2.5 μg Tiotropium Respimat ® 1.25 μg Placebo Respimat ®
(n = 76) (n = 74) (n = 75) (n = 76)
Patients with any adverse event 7 (9.2) 7 (9.5) 7 (9.3) 8 (10.5)
Asthma 2 (2.6) 2 (2.7) 1 (1.3) 1 (1.3)
Bronchitis 2 (2.6) 1 (1.4) 1 (1.3) 1 (1.3)
Headache 1 (1.3) 1 (1.4) 2 (2.7) 0
Nasopharyngitis 0 0 2 (2.7) 2 (2.6)
Pharyngitis 1 (1.3) 1 (1.4) 0 1 (1.3)
Rhinitis 0 2 (2.7) 0 1 (1.3)
Cough 0 0 0 2 (2.6)
Influenza 1 (1.3) 1 (1.4) 0 0
Purulence 0 0 1 (1.3) 0
Respiratory tract infection 0 0 0 1 (1.3)
Urinary tract infection 0 0 0 1 (1.3)
Viral upper respiratory tract infection 1 (1.3) 0 0 0
Stomatitis 0 0 0 1 (1.3)
Chest pain 1 (1.3) 0 0 0
Contusiona 0 0 0 1 (1.3)
Skeletal injury 0 0 0 1 (1.3)
  1. aContusion of the lower jaw. Treatment + 30 days.